<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Refractory Kawasaki disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Refractory Kawasaki disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Refractory Kawasaki disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marisa Klein-Gitelman, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kawasaki disease (KD), also called mucocutaneous lymph node syndrome, is one of the most common vasculitides of childhood [<a href="#rid1">1</a>]. It is typically a self-limited condition with fever and manifestations of acute inflammation lasting for an average of 12 days without therapy. However, cardiovascular complications, such as coronary artery (CA) aneurysms leading to potential occlusion and cardiac ischemia, occur in a sizeable percentage of untreated children. The major sequelae of KD are dramatically decreased as a result of therapy with intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG). Nonetheless, for decades, prolonged fever has been recognized as the strongest predictor of CA abnormalities. Thus, additional therapy is advised in patients with persistent fever after initial IVIG therapy.</p><p>The treatment of refractory KD is discussed in this review. The initial treatment of KD, diagnosis, clinical manifestations, and cardiovascular sequelae are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/6417.html" rel="external">"Kawasaki disease: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">"Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation"</a>.)</p><p class="headingAnchor" id="H623547"><span class="h1">REFRACTORY DISEASE</span></p><p class="headingAnchor" id="H2162806554"><span class="h2">Definition</span><span class="headingEndMark"> — </span>Refractory KD results from failure to abort the disease process and is defined as any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent fever of any magnitude 24 to 36 hours after completion of initial intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Return of fever of any magnitude after an afebrile period not explained by any cause other than KD (up to two weeks after the start of treatment)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other signs of failed initial therapy such as progressive coronary artery (CA) dilation or other manifestations of inflammation associated with KD (eg, nonexudative conjunctivitis)</p><p></p><p class="headingAnchor" id="H783090293"><span class="h2">Monitoring and assessment after initial therapy</span><span class="headingEndMark"> — </span>Patients should receive regular follow-up during the convalescent period regardless of whether there are any signs of smoldering vasculitis. Patients are monitored for persistent or recurrent fever after starting initial therapy. The frequency of repeat echocardiograms depends upon the degree of initial CA involvement and risk factors for CA dilation. Follow-up after initial therapy is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Follow-up'</a>.)</p><p class="headingAnchor" id="H624730"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>Fever persists or returns within 48 hours in approximately 10 to 15 percent of patients with KD who are initially treated with 2 g/kg <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> and <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">aspirin</a> [<a href="#rid1">1-4</a>]. For unclear reasons, however, this fraction can vary significantly. In 2006, the incidence of refractory KD in Boston was 8 percent. In contrast, the likelihood of having KD refractory to initial IVIG therapy in San Diego increased to 38 percent in 2006 from a range of 10 to 20 percent between 1998 and 2005 [<a href="#rid5">5</a>]. This increase was not associated with any changes in the formulations of IVIG used. In addition, the same IVIG brands and lots administered in San Diego to treat patients with KD were also used in Boston.</p><p class="headingAnchor" id="H623748"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Just as the mechanism of action of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> in KD is not understood, the reason that some patients with KD fail initial IVIG therapy is also not clear. Retrospective studies have identified demographic, clinical, and laboratory characteristics at presentation that can predict which patients are more likely to require further therapy for refractory disease. Predictive factors that have been identified repeatedly in several studies include male sex [<a href="#rid6">6</a>], age under 12 months and particularly under 6 months [<a href="#rid7">7</a>], Asian race [<a href="#rid8">8</a>], and delayed diagnosis  (<a class="graphic graphic_table graphicRef129505" href="/z/d/graphic/129505.html" rel="external">table 1</a>) [<a href="#rid9">9</a>]. Studies are ongoing to determine whether patients with identified risk factors may benefit from more aggressive initial therapy. Risk factors for IVIG resistance and for CA aneurysms are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Identification of patients at high risk for IVIG resistance'</a> and  <a class="medical medical_review" href="/z/d/html/15688.html" rel="external">"Kawasaki disease: Complications", section on 'Coronary artery abnormalities'</a>.)</p><p class="headingAnchor" id="H625620"><span class="h2">Other causes of fever</span><span class="headingEndMark"> — </span>In general, a child diagnosed with KD who has persistent or recurrent fever plus one or more of the presenting signs of mucocutaneous inflammation 36 hours after the start of the <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> infusion is likely to have refractory disease. However, fever plus the appearance of manifestations of an infection, macrophage activation syndrome (MAS), or other conditions should lead to evaluation for other causes of fever.</p><p class="bulletIndent1"><span class="glyph">●</span>Fever that occurs during or within 36 hours after the <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> infusion may be due to a reaction to the medication [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intercurrent infection or MAS (a form of hemophagocytic lymphohistiocytosis) [<a href="#rid11">11</a>] are other potential causes of recurrent or prolonged fever in patients with KD. (See  <a class="medical medical_review" href="/z/d/html/6075.html" rel="external">"Fever without a source in children 3 to 36 months of age: Evaluation and management"</a> and  <a class="medical medical_review" href="/z/d/html/5993.html" rel="external">"Fever of unknown origin in children: Evaluation", section on 'Overview of evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternative diagnoses, such as autoinflammatory diseases, systemic juvenile idiopathic arthritis (sJIA) or a chronic vasculitis (eg, polyarteritis nodosa), also should be considered when findings of KD are prolonged beyond three to four weeks. (See  <a class="medical medical_review" href="/z/d/html/6413.html" rel="external">"Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification"</a> and  <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multisystem inflammatory syndrome in children (MIS-C) is an uncommon complication of coronavirus disease 19 (COVID-19) that has a presentation similar to KD. The clinical presentation of MIS-C may include persistent fevers, gastrointestinal symptoms (abdominal pain, vomiting, diarrhea), rash, and conjunctivitis. Compared with patients with classic KD, these patients have a higher median age of onset, higher C-reactive protein (CRP) and D-dimer values, and more commonly have other cardiac complications including myocardial dysfunction and shock. (See  <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2545703812"><span class="h1">TREATMENT APPROACH</span></p><p class="headingAnchor" id="H7"><span class="h2">Initial salvage therapy</span></p><p class="headingAnchor" id="H2602526325"><span class="h3">Rationale</span><span class="headingEndMark"> — </span>Patients who fail to respond to the initial dose of intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) are at increased risk, up to 10-fold, of developing coronary artery (CA) abnormalities and long-term sequelae of the disease [<a href="#rid12">12-15</a>]. The duration of fever correlates with the risk of developing CA aneurysms [<a href="#rid1">1</a>]. Ideally, high-risk patients should be identified prospectively, before CA abnormalities develop, allowing supplemental therapy to prevent or ameliorate vascular damage. However, even patients who receive augmented initial therapy may not respond. (See <a class="local">'Risk factors'</a> above and  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Identification of patients at high risk for IVIG resistance'</a>.)</p><p class="headingAnchor" id="H821547058"><span class="h3">Indications</span><span class="headingEndMark"> — </span>Indications for salvage therapy include persistence or recurrence of fever or other ongoing signs of inflammation consistent with KD, including progressive CA dilation [<a href="#rid16">16,17</a>]. These patients should be retreated for presumed resistant KD unless there is clear evidence that persistent or recrudescent fever is <strong>not </strong>due to KD. Fever within 36 hours of the start of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> therapy does not necessarily warrant retreatment, because it may represent a reaction to the medication or a slow response to therapy. However, salvage therapy is indicated, even within 36 hours of initial IVIG therapy, if such temperature elevations are associated with other signs or symptoms of KD or abnormal or expanding CAs. Patients should also be evaluated for other causes of fever. (See <a class="local">'Definition'</a> above and <a class="local">'Other causes of fever'</a> above and  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Follow-up'</a>.)</p><p class="headingAnchor" id="H2735798333"><span class="h3">Choice of agent</span><span class="headingEndMark"> — </span>Therapeutic options for initial salvage (rescue) therapy are based upon agents that have demonstrated effectiveness in other vasculitides and include systemic glucocorticoids, biologic response modifiers such as <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> (a tumor necrosis factor [TNF] inhibitor), and/or a second dose of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>  (<a class="graphic graphic_algorithm graphicRef131240" href="/z/d/graphic/131240.html" rel="external">algorithm 1</a>) [<a href="#rid18">18</a>]. More potent immunosuppressive agents such as <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a> or <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> are typically reserved for CA disease that is more severe or refractory to numerous other treatments.</p><p>These salvage therapies have demonstrated resolution of fever in small randomized trials and observational studies. However, while many salvage therapies appear to control fever in children with KD, high-quality controlled clinical trials with CA outcomes are largely lacking. The tendency is for the clinician to layer on numerous additional therapies in children with KD who remain febrile or whose CAs are continuing to dilate. Consequently, it is not possible to determine which agent is actually effective. In addition, fever in KD is self-limiting, and apparent response to therapy reported in uncontrolled studies may represent abatement of the disease process that is not directly related to the therapy administered.</p><p>Thus, clinicians are left with numerous imperfect options and inadequate data to make a fully informed choice when their patient remains febrile and is at high risk of developing CA abnormalities [<a href="#rid19">19</a>]. More precise genetic characterization of children who develop the disease, as well as a better understanding of the factors that mediate persistent inflammation and affect outcomes, may one day allow clinicians to tailor therapy to an individual child's needs.</p><p class="headingAnchor" id="H464774270"><span class="h3">Standard agents</span><span class="headingEndMark"> — </span>Standard salvage therapy agents include glucocorticoids, <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a>, and <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>.</p><p class="headingAnchor" id="H8"><span class="h4">Glucocorticoid therapy</span><span class="headingEndMark"> — </span>For most patients with refractory KD, we suggest glucocorticoid therapy as the initial agent for salvage therapy. Exceptions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who received or are receiving glucocorticoids as part of the initial treatment regimen. <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">Infliximab</a> and/or a second dose of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> are reasonable options for such patients. (See <a class="local">'TNF inhibition (infliximab)'</a> below and <a class="local">'Intravenous immune globulin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients in the highest-risk category (eg, those with giant CA aneurysms or progressive CA dilation), in whom combination therapy or more potent immunosuppressive therapy may be preferred. (See <a class="local">'Options for higher-risk patients'</a> below.)</p><p></p><p>Use of glucocorticoid therapy for refractory KD is supported by observational studies, limited clinical trial data, and indirect evidence from other vasculitides [<a href="#rid2">2,12-14,20-26</a>]. In these studies, many patients had a good clinical response, with persistent resolution of fevers in the majority of patients and rates of CA aneurysms similar to those reported in patients who received an additional dose of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>. Use is also indirectly based upon the response of high-risk patients to initial therapy that is augmented with glucocorticoids [<a href="#rid27">27</a>]. Severe adverse effects from a two- to three-week course of glucocorticoids are rare, whereas IVIG retreatment is associated with a dose-dependent risk of hemolytic anemia in patients with non-O blood types. There is greater clinical experience with glucocorticoids than with more costly biologic response modifiers (eg, <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a>, <a class="drug drug_pediatric" data-topicid="13284" href="/z/d/drug information/13284.html" rel="external">etanercept</a>, <a class="drug drug_pediatric" data-topicid="13251" href="/z/d/drug information/13251.html" rel="external">anakinra</a>), but data directly comparing these treatments are lacking. (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Glucocorticoids'</a>.)</p><p>In a meta-analysis of six studies (two small randomized trials and four observational studies) involving a total of 383 patients with refractory KD, rates of CA abnormalities were similar with glucocorticoid therapy or repeat <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> (odds ratio [OR] 0.85, 95% CI 0.57-1.56) [<a href="#rid21">21</a>]. Two other meta-analyses reported similar findings [<a href="#rid20">20,22</a>]. The first meta-analysis also found that the effects of glucocorticoids in KD were inversely proportional to the amount of time that has passed since disease onset [<a href="#rid21">21</a>]. One meta-analysis reported that more patients had fever resolution with glucocorticoid therapy compared with repeat IVIG (83 versus 62 percent; relative risk [RR] 1.36, 95% CI 1.09-1.72), based on a pooled estimate from four studies (n = 127) reporting this outcome [<a href="#rid22">22</a>].</p><p>Various glucocorticoid regimens are used in patients who fail to respond to <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> therapy, generally paralleling glucocorticoid regimens for augmented initial therapy of KD. (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Additional therapy for patients at high risk for IVIG resistance'</a>.)</p><p>We usually start children on 1 mg/kg <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> equivalent twice daily for five days, after which the dose is decreased to 1 mg/kg daily for five days, and then, for the last five days, 0.5 mg/kg daily. We do not extend patients' hospitalization solely to administer glucocorticoids intravenously. Patients who have defervesced and have stable to improving CA dilatation are switched to oral prednisone for home treatment one day before the anticipated hospital discharge. Depending upon the degree of CA dilatation, patients may be observed longer in the hospital or may have frequent outpatient lab tests and echocardiograms. Patients who do not continue to improve or whose CA diameters increase on oral glucocorticoids are considered to have failed glucocorticoid therapy and are usually treated with <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a>. (See <a class="local">'TNF inhibition (infliximab)'</a> below and <a class="local">'Cyclosporine'</a> below.)</p><p>Our approach differs from practice in Japan, where children are usually hospitalized for the entire glucocorticoid course and salvage therapy is based upon the RAISE protocol [<a href="#rid27">27</a>]. The RAISE approach typically consists of <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> at a starting dose of 2 mg/kg/day intravenously [IV] divided three times daily for five days. Patients are switched to oral prednisolone if the fever defervesces after the first five days of treatment. The prednisolone taper (1 mg/kg/day to 0.5 mg/kg/day in five-day steps) is started once C-reactive protein (CRP) is within the normal range (≤5 mg/L) and the patient has received at least five days of the 2 mg/kg/day dose.</p><p>An alternative to the 15-day glucocorticoid taper is IV pulsed-dose <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">methylprednisolone</a> (30 mg/kg per day) for up to three consecutive days.</p><p>Serious side effects from even a two- to three-week course of glucocorticoids are unusual. Rarely, a child may develop a dramatic leukemoid reaction, with absolute neutrophil counts spiking to 80,000/mm<sup>3</sup>, but the leukocytosis has not been associated with identifiable ill effects. The reaction rapidly reverses when the glucocorticoids are tapered or discontinued. Other side effects are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H10"><span class="h4">TNF inhibition (infliximab)</span><span class="headingEndMark"> — </span>Anti-tumor necrosis factor (TNF) alpha agents have been studied for the treatment of KD because elevated levels of TNF are a characteristic of KD [<a href="#rid28">28</a>]. Treatment of IVIG-resistant cases of KD with <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a>, a chimeric monoclonal antibody that binds to TNF-alpha, is associated with a rapid, and apparently safe, lowering of fever and normalization of proinflammatory cytokines but not markers of cell-mediated vasculitis [<a href="#rid29">29-33</a>]. As with glucocorticoids, however, TNF inhibition has not convincingly been demonstrated to affect the development of CA abnormalities [<a href="#rid34">34</a>].</p><p>In the one small, randomized, multicenter trial, patients who failed an initial dose of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> were randomly selected to receive either an IV dose of <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> (5 mg/kg) or a second dose of IVIG (2 g/kg) [<a href="#rid29">29</a>]. Fever resolved within 24 hours in 11 of 12 patients treated with infliximab and 8 of 12 who received a second dose of IVIG. Two of the four patients who failed to respond to the second dose of IVIG responded with fever resolution after crossing over to infliximab, and the one patient who initially failed to respond to infliximab responded to a second IVIG infusion. Progression of echocardiographic changes in CAs was similar between the two groups. There were no severe adverse events directly attributed to treatment in either group. Transient hepatomegaly (but with normal serum alanine aminotransferase [ALT]) was observed in five patients from the infliximab group and one from the IVIG group. Three patients treated with infliximab developed low-titer antibodies to infliximab. Findings were similar in a subsequent larger retrospective review [<a href="#rid30">30</a>]. As with glucocorticoids, a Korean study found that benefits of infliximab are more pronounced when the TNF inhibitor is administered earlier in the patient's course [<a href="#rid35">35</a>].</p><p>The potential adverse events associated with long-term use of TNF inhibitors, including infection and malignancy, are reviewed in greater detail separately. The focused but potentially prolonged immunosuppressive effects of agents such as <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> can lead to significant complications in some patients, particularly children with infections mimicking or coincident with KD. In general, however, few serious adverse effects have been reported in association with use of immunosuppressive agents in KD. Presumably this is because KD is a self-limited condition, so patients do not need prolonged, repeat dosing of second-line agents. Unlike long-term use in chronic diseases, children have brief exposure to the medications and therefore have less profound suppression of cytokines, lymphocytes, and neutrophils. (See  <a class="medical medical_review" href="/z/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment", section on 'Biologic disease-modifying antirheumatic drug (DMARD) therapy'</a> and  <a class="medical medical_review" href="/z/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment", section on 'Tumor necrosis factor alpha inhibitors'</a>.)</p><p class="headingAnchor" id="H4133498666"><span class="h4">Intravenous immune globulin</span><span class="headingEndMark"> — </span>The first agent examined for therapy of children with persistent fevers after receiving <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> was retreatment with additional IVIG. At the time, IVIG was the only agent shown to be effective for treatment of KD, and it was known to have a positive dose-response [<a href="#rid36">36</a>]. There are no prospective trials demonstrating a beneficial effect of retreatment with IVIG on CA outcomes, although observational studies suggest that the majority of patients with persistent fever after initial IVIG therapy will have resolution of their fevers after retreatment with IVIG [<a href="#rid1">1,3,37</a>]. Nonetheless, cumulative doses of IVIG above 4 g/kg typically do not demonstrate additional benefit in KD [<a href="#rid1">1,36,38</a>]. Thus, IVIG retreatment of persistently febrile children is usually limited to one additional infusion of IVIG (up to 2 g/kg) for a maximum total cumulative IVIG dose of 4 g/kg  (<a class="graphic graphic_algorithm graphicRef131240" href="/z/d/graphic/131240.html" rel="external">algorithm 1</a>).</p><p><a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> retreatment also carries a dose-related risk of causing hemolytic anemia, with up to 15 percent of children receiving 4 g/kg requiring transfusions [<a href="#rid39">39</a>]. The hemolysis is due to antibodies against major blood types in IVIG. Children with type AB blood are at highest risk, while those with type O do not develop hemolysis. Consequently, we favor glucocorticoids over a second dose of IVIG in children with blood types A, B, or AB who are refractory to the first dose of IVIG.</p><p class="headingAnchor" id="H4029887235"><span class="h3">Options for higher-risk patients</span><span class="headingEndMark"> — </span>For higher-risk patients with refractory KD (ie, patients with giant CA aneurysms [Z-score ≥10] or smaller CA aneurysms that are increasing in size), we suggest combination therapy rather than single-agent salvage therapy. Combination therapy typically consists of a second dose of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> plus a 15-day glucocorticoid taper or <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a>. In addition, more potent immunosuppressive agents (eg, <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a> or <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>) are used in some cases.</p><p class="headingAnchor" id="H3254760873"><span class="h4">Combination therapy</span><span class="headingEndMark"> — </span>Limited data suggest that combination therapy (use of two of the following: <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>, glucocorticoids, <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a>) may have a greater impact on CA outcomes than monotherapy, although this benefit diminishes as time from onset of illness to start of salvage therapy increases.</p><p>One multicenter, retrospective study showed improved outcomes in small numbers of children receiving either glucocorticoids plus <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> or <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> plus IVIG compared with those receiving IVIG alone [<a href="#rid16">16</a>].</p><p>A retrospective study of 359 consecutive patients in Japan between 2000 and 2011 compared outcomes in children with <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> resistance treated with 2 mg/kg of <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> alone, tapered over at least 15 days; a second 1 or 2 g/kg dose of IVIG; or both tapering prednisolone and a second dose of IVIG. CA abnormalities up to one month after treatment were evident in 28.7 percent of children who received a second IVIG dose, in 30.6 percent of those who were treated with prednisolone alone, and in 15.9 percent who received both IVIG plus prednisolone [<a href="#rid24">24</a>]. Patients in the groups differed significantly in mean age and date of treatment, factors known to affect the risk of developing CA abnormalities. Unfortunately, the results are not definitive due to the nature of retrospective observational studies. Additionally, there was no concurrent placebo-control group, so it is not possible to know whether IVIG or prednisolone alone had any beneficial effect.</p><p>As noted above, a systematic review and meta-analysis of 16 studies involving 2746 patients treated with <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> plus glucocorticoids (initial or rescue therapy) versus IVIG alone found that the efficacy of glucocorticoids in protecting CAs was inversely related to the duration of illness before glucocorticoids were administered [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3084784210"><span class="h4">Cyclosporine</span><span class="headingEndMark"> — </span>Among genetic variants associated with susceptibility to KD are the inositol-trisphosphate 3-kinase C (<em>ITPKC</em>) and caspase 3 (<em>CASP3</em>) genes, which are thought to increase signaling through the calcium nuclear factor of activated T cells (<em>NFAT</em>) pathway. This led to interest in possible therapeutic effects of calcineurin inhibitors such as <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a>, which target this pathway [<a href="#rid17">17</a>]. One study in Japan showed that 22 of 28 patients resistant to two doses of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> defervesced within five days of treatment with cyclosporine [<a href="#rid40">40</a>]. In an open-label, blinded-endpoints trial of initial therapy, 174 patients predicted to be at high risk of having IVIG resistance (Kobayashi score &gt;5) were randomly assigned to 5 mg/kg cyclosporine orally divided twice daily for five days in addition to routine IVIG 2 g/kg and <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">aspirin</a> 30 mg/kg/day or routine therapy without cyclosporine [<a href="#rid41">41</a>]. A lower rate in the primary endpoint of incidence of CA abnormalities from treatment day 3 to week 12 was seen in the group treated with cyclosporine (RR 0.46, 95% CI 0.25-0.86), but this is not a validated outcome measure. Secondary validated endpoints did not confirm a CA benefit in the patients treated with cyclosporine, with no change in mean Z-scores in each CA segment and no difference in CA abnormalities between the two groups at weeks 1, 4, and 12.</p><p class="headingAnchor" id="H3218069249"><span class="h4">Cyclophosphamide</span><span class="headingEndMark"> — </span>At least one group with considerable experience in the diagnosis and treatment of KD has reported treating severe refractory cases with <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> [<a href="#rid42">42</a>]. In view of its efficacy in other pediatric vasculitides of medium-sized arteries, we have treated 10 patients refractory to multiple courses of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>, glucocorticoids, <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a>, and <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> with 10 mg/kg cyclophosphamide [<a href="#rid43">43</a>]. In seven of the patients, fever and coronary dilatation ceased to continue after one dose of cyclophosphamide, and the other three improved after a second cyclophosphamide dose one week later. In all cases, improvement occurred shortly after the dose of cyclophosphamide, though it is not possible to know if these patients might have resolution of signs and symptoms without addition of cyclophosphamide.</p><p class="headingAnchor" id="H531002502"><span class="h2">Subsequent salvage therapy</span></p><p class="headingAnchor" id="H143406438"><span class="h3">Rationale</span><span class="headingEndMark"> — </span>Children who continue to have evidence of active vasculitis despite initial salvage therapy are at particularly high risk of developing severe CA changes. The degree of CA dilatation corresponds with morbidity and mortality in KD.</p><p class="headingAnchor" id="H3771789827"><span class="h3">Choice of therapy</span><span class="headingEndMark"> — </span>The general practice is to add agents thought to be more potent in children with larger aneurysms. Thus, after salvage treatment with <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> plus glucocorticoids, a child with a moderate-sized CA aneurysm (Z-score 3 to &lt;10) may be given <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a>. More severely affected children with giant CA aneurysms (Z-score ≥10) may receive <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> or plasmapheresis in an attempt to rapidly arrest the vasculitis and slow or arrest the CA dilatation with minimal additional injury.</p><p>Neither the efficacy of such rescue therapies nor the optimal sequence of their use have been compared in controlled trials, and only small numbers of case reports are in the literature. In addition, some of the treatments have the potential to cause more serious toxicity compared with initial salvage therapy agents. Thus, these therapies should be given under the supervision of a clinician with expertise in treating children with KD and managing immunosuppressed patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong><strong>/</strong><strong>cyclophosphamide</strong><strong> </strong>–<strong> </strong>Therapy with <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a> or <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> is a commonly chosen option for a second course of salvage treatment. These agents are discussed in greater detail above. (See <a class="local">'Cyclosporine'</a> above and <a class="local">'Cyclophosphamide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmapheresis </strong>–<strong> </strong>Plasmapheresis is generally most effective in acute inflammatory conditions, whereas it seems to lack long-term benefit in chronic diseases. Thus, KD appears to be an ideal disorder for this intervention. On the other hand, plasmapheresis is a technically complex and medically hazardous intervention, restricting its utility in a self-limited condition such as KD [<a href="#rid44">44</a>]. In view of the risks associated with plasmapheresis, as well as the potential efficacy of alternative salvage regimens, we reserve plasmapheresis for children who have active vasculitis despite multiple doses of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>, glucocorticoids, and a trial of <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a>. (See  <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a>.)</p><p></p><p class="bulletIndent1">Despite its limitations, rare case reports of apparent dramatic responses of KD to plasmapheresis appeared in the literature during the time period in which glucocorticoids were viewed as contraindicated [<a href="#rid45">45,46</a>]. In a nonrandomized study of 75 children with KD who were unresponsive to two doses of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>, 27 children underwent plasmapheresis, and 48 received an additional dose of IVIG [<a href="#rid47">47</a>]. A lower percentage of children in the plasmapheresis group developed CA lesions (11 versus 48 percent in the IVIG group). In another such study, six patients unresponsive to two doses of IVIG and one dose of <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> were treated with plasmapheresis [<a href="#rid31">31</a>]. All six patients defervesced, had resolution of clinical symptoms, and improvement in laboratory abnormalities. CA outcomes, however, were not reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interleukin 1 inhibition </strong>–<strong> </strong>KD and systemic juvenile idiopathic arthritis (sJIA) share several phenotypic and epidemiologic characteristics, as well as evidence of elevated levels of interleukin (IL) 1 [<a href="#rid48">48</a>]. In addition, IL-1-induced inflammation has been shown to play a role in acute myocardial infarction and in the development of CA vasculitis in the <em>Lactobacillus casei</em> cell-wall extract mouse model of KD [<a href="#rid49">49</a>]. This has led to several trials using <a class="drug drug_pediatric" data-topicid="13251" href="/z/d/drug information/13251.html" rel="external">anakinra</a>, a short-acting competitive inhibitor of IL-1 binding to the IL-1 type 1 receptor (IL-1R1), or <a class="drug drug_pediatric" data-topicid="17066" href="/z/d/drug information/17066.html" rel="external">canakinumab</a>, a monoclonal antibody against IL-1-beta [<a href="#rid50">50</a>]. Preliminary data suggest that these agents are safe in children with KD, but efficacy information is not yet available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interleukin 6 inhibition </strong>– <a class="drug drug_pediatric" data-topicid="88097" href="/z/d/drug information/88097.html" rel="external">Tocilizumab</a>, a novel anti-IL-6 monoclonal antibody, has been used in several cases of IVIG-nonresponsive KD, although its effectiveness has been inconsistent [<a href="#rid51">51</a>]. In one case series, two of four patients with refractory KD who were treated with tocilizumab developed giant CA aneurysms despite rapid improvement in fever, other clinical symptoms, and laboratory measures [<a href="#rid52">52</a>]. This finding raises the concern that IL-6 blockers such as tocilizumab may disrupt the process of reparative inflammation, thereby increasing the risk of CA aneurysms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other TNF inhibition</strong> –<strong> </strong><a class="drug drug_pediatric" data-topicid="13284" href="/z/d/drug information/13284.html" rel="external">Etanercept</a> is a recombinant protein that binds tumor necrosis factor (TNF) alpha and blocks its interaction with TNF receptors. In a randomized, controlled trial of adjunctive therapy for high-risk patients, children over one year of age had less <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> resistance if they received etanercept immediately after the initial dose of IVIG than those who did not receive etanercept [<a href="#rid53">53</a>]. There is one case report of its use in addition to <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">methotrexate</a> in a refractory case of KD [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Tumor necrosis factor inhibition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Miscellaneous</strong> –<strong> </strong><a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">Rituximab</a>, a B cell-depleting monoclonal anti-CD20 antibody, was administered in a single case involving a child with KD refractory to <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> and glucocorticoids [<a href="#rid55">55</a>]. The child had rapid resolution of clinical signs and symptoms of KD, including CA findings and laboratory abnormalities.</p><p></p><p class="bulletIndent1">Many other agents, including <a class="drug drug_pediatric" data-topicid="12694" href="/z/d/drug information/12694.html" rel="external">pentoxifylline</a> [<a href="#rid56">56</a>], antioxidants [<a href="#rid57">57</a>], and neutrophil-elastase inhibitors [<a href="#rid58">58</a>], have been studied for the treatment of refractory KD, but their efficacy remains unclear.</p><p></p><p class="headingAnchor" id="H1139848587"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>The complications associated with KD, prognosis, and recommended follow-up (including echocardiography to evaluate for coronary artery [CA] involvement) are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Complications'</a> and  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Follow-up'</a>.)</p><p class="headingAnchor" id="H1693491422"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110198.html" rel="external">"Society guideline links: Kawasaki disease"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of and risk factors for refractory Kawasaki disease</strong> – Some patients with Kawasaki disease (KD) have persistent or recurrent fever despite treatment with intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) and <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">aspirin</a> with or without glucocorticoids. Refractory KD refers to patients with <strong>any</strong> of the following (see <a class="local">'Refractory disease'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent fever 24 to 36 hours after completion of initial <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Return of fever after an afebrile period (up to two weeks after the start of treatment)</p><p class="bulletIndent2"><span class="glyph">•</span>Other signs of failed initial therapy such as progressive coronary artery (CA) dilation</p><p></p><p class="bulletIndent1">Risk factors for <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> resistance include male sex, age under six months, elevated C-reactive protein (CRP), CA dilatation at presentation, and low sodium or platelet levels. In patients with prolonged or recurrent fever, other causes of fever should be considered. (See <a class="local">'Refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment for refractory KD</strong> – Patients with refractory KD require additional therapy because they are at increased risk of developing CA aneurysms and CA sequelae. The ultimate goal of salvage therapy is to prevent or minimize CA complications, but no salvage agent unequivocally has been shown to achieve this goal in all children who have failed to respond to initial <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>. Choice of therapy depends upon degree of CA involvement, prior treatments used, and the clinician's preference. Our general approach is as follows  (<a class="graphic graphic_algorithm graphicRef131240" href="/z/d/graphic/131240.html" rel="external">algorithm 1</a>) (see <a class="local">'Initial salvage therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No prior glucocorticoid therapy</strong> – For most patients with refractory KD who have not received prior glucocorticoid therapy, we suggest glucocorticoid treatment rather than other salvage therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically treat with a 15-day tapering course of <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> or <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a>. Reasonable alternatives are a single dose of <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> (5 mg/kg), a tumor necrosis factor (TNF) alpha inhibitor, or retreatment with a single dose of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> (2 g/kg). We typically do not choose a repeat dose of IVIG over glucocorticoid therapy in patients with blood type AB, A, or B, because of the risk of hemolytic anemia in this setting. (See <a class="local">'Glucocorticoid therapy'</a> above and <a class="local">'TNF inhibition (infliximab)'</a> above and <a class="local">'Intravenous immune globulin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Higher-risk patients</strong> – For higher-risk patients with refractory KD (ie, patients with giant CA aneurysms [Z-score ≥10] or smaller CA aneurysms that are increasing in size), we suggest combination therapy rather than single-agent salvage therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Combination therapy typically consists of a second dose of <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> plus a 15-day glucocorticoid taper or <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a>. In addition, more potent immunosuppressive agents (eg, <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a> or <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>) are used in some cases. (See <a class="local">'Initial salvage therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients who failed initial salvage therapy</strong> – For patients who fail the first course of salvage therapy, subsequent treatment options include other immunosuppressive agents (eg, <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>, <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a>) and plasmapheresis. The choice among these depends upon degree of CA involvement and prior treatments used. There are limited data concerning the risks and benefits of these agents for refractory KD and only a few, small trials with which to evaluate them. (See <a class="local">'Subsequent salvage therapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998; 17:1144.</a></li><li><a class="nounderline abstract_t">Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001; 43:211.</a></li><li><a class="nounderline abstract_t">Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008; 27:155.</a></li><li><a class="nounderline abstract_t">Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149:237.</a></li><li><a class="nounderline abstract_t">Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008; 153:117.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol 2012; 22:216.</a></li><li><a class="nounderline abstract_t">Honkanen VE, McCrindle BW, Laxer RM, et al. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol 2003; 24:122.</a></li><li><a class="nounderline abstract_t">Belay ED, Maddox RA, Holman RC, et al. Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003. Pediatr Infect Dis J 2006; 25:245.</a></li><li><a class="nounderline abstract_t">Anderson MS, Todd JK, Glodé MP. Delayed diagnosis of Kawasaki syndrome: an analysis of the problem. Pediatrics 2005; 115:e428.</a></li><li><a class="nounderline abstract_t">Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356:663.</a></li><li><a class="nounderline abstract_t">Kang HR, Kwon YH, Yoo ES, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease. Blood Res 2013; 48:254.</a></li><li><a class="nounderline abstract_t">Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996; 128:146.</a></li><li><a class="nounderline abstract_t">Venugopalan P, Jaya S, Al-Azri MA, Piopongco E. Kawasaki disease resistant to immunoglobulin G therapy. Ann Trop Paediatr 2003; 23:187.</a></li><li><a class="nounderline abstract_t">Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J 2001; 20:635.</a></li><li><a class="nounderline abstract_t">Yan F, Pan B, Sun H, et al. Risk Factors of Coronary Artery Abnormality in Children With Kawasaki Disease: A Systematic Review and Meta-Analysis. Front Pediatr 2019; 7:374.</a></li><li><a class="nounderline abstract_t">Dionne A, Burns JC, Dahdah N, et al. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">Onouchi Y, Suzuki Y, Suzuki H, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J 2013; 13:52.</a></li><li><a class="nounderline abstract_t">Song MS. Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease. Korean J Pediatr 2019; 62:119.</a></li><li><a class="nounderline abstract_t">Sundel R. Clarifying the Role of Corticosteroids in Kawasaki Disease. JAMA Pediatr 2016; 170:1140.</a></li><li><a class="nounderline abstract_t">Chan H, Chi H, You H, et al. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease. BMC Pediatr 2019; 19:158.</a></li><li><a class="nounderline abstract_t">Chen S, Dong Y, Kiuchi MG, et al. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis. JAMA Pediatr 2016; 170:1156.</a></li><li><a class="nounderline abstract_t">Yang X, Liu G, Huang Y, et al. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease. Cardiol Young 2015; 25:1182.</a></li><li><a class="nounderline abstract_t">Shetty AK, Homsi O, Ward K, Gedalia A. Massive lymphadenopathy and airway obstruction in a child with Kawasaki disease: success with pulse steroid therapy. J Rheumatol 1998; 25:1215.</a></li><li><a class="nounderline abstract_t">Kobayashi T, Kobayashi T, Morikawa A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr 2013; 163:521.</a></li><li><a class="nounderline abstract_t">Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003; 142:611.</a></li><li><a class="nounderline abstract_t">Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008; 93:142.</a></li><li><a class="nounderline abstract_t">Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379:1613.</a></li><li><a class="nounderline abstract_t">Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr 1992; 121:924.</a></li><li><a class="nounderline abstract_t">Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008; 153:833.</a></li><li><a class="nounderline abstract_t">Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011; 158:644.</a></li><li><a class="nounderline abstract_t">Sonoda K, Mori M, Hokosaki T, Yokota S. Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr 2014; 164:1128.</a></li><li><a class="nounderline abstract_t">Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009; 65:696.</a></li><li><a class="nounderline abstract_t">Masuda H, Kobayashi T, Hachiya A, et al. Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan. J Pediatr 2018; 195:115.</a></li><li><a class="nounderline abstract_t">Yamaji N, da Silva Lopes K, Shoda T, et al. TNF-α blockers for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2019; 8:CD012448.</a></li><li><a class="nounderline abstract_t">Hur G, Song MS, Sohn S, et al. Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea. Korean Circ J 2019; 49:183.</a></li><li><a class="nounderline abstract_t">Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324:1633.</a></li><li><a class="nounderline abstract_t">Han RK, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 2000; 154:694.</a></li><li><a class="nounderline abstract_t">Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124:1.</a></li><li><a class="nounderline abstract_t">Luban NL, Wong EC, Henrich Lobo R, et al. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease. Transfusion 2015; 55 Suppl 2:S90.</a></li><li><a class="nounderline abstract_t">Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 2011; 30:871.</a></li><li><a class="nounderline abstract_t">Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet 2019; 393:1128.</a></li><li><a class="nounderline abstract_t">Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000; 105:E78.</a></li><li><a class="nounderline abstract_t">Halyabar O, Friedman KG, Sundel RP, et al. Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms. Pediatr Rheumatol Online J 2021; 19:31.</a></li><li><a class="nounderline abstract_t">Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747.</a></li><li><a class="nounderline abstract_t">Villain E, Kachaner J, Sidi D, et al. [Trial of prevention of coronary aneurysm in Kawasaki's disease using plasma exchange or infusion of immunoglobulins]. Arch Fr Pediatr 1987; 44:79.</a></li><li><a class="nounderline abstract_t">Netter JC, Fries F, Rajon AM, et al. [Exchange transfusion in a case of Kawasaki syndrome]. Arch Fr Pediatr 1982; 39:699.</a></li><li><a class="nounderline abstract_t">Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004; 163:263.</a></li><li><a class="nounderline abstract_t">Dusser P, Koné-Paut I. IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease. Front Pharmacol 2017; 8:163.</a></li><li><a class="nounderline abstract_t">Wakita D, Kurashima Y, Crother TR, et al. Role of Interleukin-1 Signaling in a Mouse Model of Kawasaki Disease-Associated Abdominal Aortic Aneurysm. Arterioscler Thromb Vasc Biol 2016; 36:886.</a></li><li><a class="nounderline abstract_t">Burns JC, Koné-Paut I, Kuijpers T, et al. Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease. Arthritis Rheumatol 2017; 69:268.</a></li><li class="breakAll">Sundel R, Harvard University, 2012, personal communication.</li><li><a class="nounderline abstract_t">Nozawa T, Imagawa T, Ito S. Coronary-Artery Aneurysm in Tocilizumab-Treated Children with Kawasaki's Disease. N Engl J Med 2017; 377:1894.</a></li><li><a class="nounderline abstract_t">Portman MA, Dahdah NS, Slee A, et al. Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">de Magalhães CM, Alves NR, de Melo AV, et al. Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge. Pediatr Rheumatol Online J 2012; 10:28.</a></li><li><a class="nounderline abstract_t">Sauvaget E, Bonello B, David M, et al. Resistant Kawasaki disease treated with anti-CD20. J Pediatr 2012; 160:875.</a></li><li><a class="nounderline abstract_t">Furukawa S, Matsubara T, Umezawa Y, et al. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Eur J Pediatr 1994; 153:663.</a></li><li><a class="nounderline abstract_t">Shen CT, Wang NK. Antioxidants may mitigate the deterioration of coronary arteritis in patients with Kawasaki disease unresponsive to high-dose intravenous gamma-globulin. Pediatr Cardiol 2001; 22:419.</a></li><li><a class="nounderline abstract_t">Zaitsu M, Hamasaki Y, Tashiro K, et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis 2000; 181:1101.</a></li></ol></div><div id="topicVersionRevision">Topic 6408 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9877364" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380911" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18174868" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16887442" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18571548" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Resistance to intravenous immunoglobulin in children with Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22447211" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12457252" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511388" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805345" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Delayed diagnosis of Kawasaki syndrome: an analysis of the problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17301297" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24466549" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8551407" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14567834" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Kawasaki disease resistant to immunoglobulin G therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419513" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31612117" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk Factors of Coronary Artery Abnormality in Children With Kawasaki Disease: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31048414" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21987091" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30999718" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27749946" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clarifying the Role of Corticosteroids in Kawasaki Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31101091" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27749951" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25597708" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9632089" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Massive lymphadenopathy and airway obstruction in a child with Kawasaki disease: success with pulse steroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23485027" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12838187" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962370" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22405251" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1447658" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18672254" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21129756" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24560183" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Infliximab plus plasma exchange rescue therapy in Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19430379" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29224935" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31425625" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : TNF-αblockers for the treatment of Kawasaki disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30468032" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1709446" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10891021" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564276" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26174904" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21587094" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30853151" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10835091" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Initial intravenous gammaglobulin treatment failure in Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33731148" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505111" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3555382" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : [Trial of prevention of coronary aneurysm in Kawasaki's disease using plasma exchange or infusion of immunoglobulins].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7165465" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : [Exchange transfusion in a case of Kawasaki syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14986117" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Plasma exchange for refractory Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28400731" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26941015" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Role of Interleukin-1 Signaling in a Mouse Model of Kawasaki Disease-Associated Abdominal Aortic Aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27792871" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27792871" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29117496" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Coronary-Artery Aneurysm in Tocilizumab-Treated Children with Kawasaki's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31048415" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22929725" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341587" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Resistant Kawasaki disease treated with anti-CD20.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7957426" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11526424" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antioxidants may mitigate the deterioration of coronary arteritis in patients with Kawasaki disease unresponsive to high-dose intravenous gamma-globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720537" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
